Standout Papers

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PAR... 2011 2026 2016 2021 1.2k
  1. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial (2011)
    Christopher M. Nutting, James P. Morden et al. The Lancet Oncology
  2. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial (2014)
    Marcia S. Brose, Christopher M. Nutting et al. The Lancet
  3. PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer (2016)
    Hisham Mehanna, Wai‐Lup Wong et al. New England Journal of Medicine
  4. Stereotactic body radiotherapy for oligometastases (2012)
    Alison Tree, Vincent Khoo et al. The Lancet Oncology

Immediate Impact

3 by Nobel laureates 8 from Science/Nature 115 standout
Sub-graph 1 of 18

Citing Papers

Radiotherapy toxicities: mechanisms, management, and future directions
2025 Standout
Thyroid Cancer
2024 Standout
43 intermediate papers

Works of Christopher M. Nutting being referenced

Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
2021
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
2014 Standout
and 15 more

Author Peers

Author Last Decade Papers Cites
Christopher M. Nutting 3350 3607 2446 2515 190 9.7k
Kate Newbold 1881 2043 2280 2120 141 8.9k
William H. Morrison 9471 5404 7066 5305 258 14.9k
Eric J. Sherman 2775 2310 2593 3194 261 8.3k
Merrill S. Kies 5611 5225 5065 7226 177 14.3k
Francis P. Worden 3447 2224 3020 3354 250 8.8k
Richard J. Wong 3231 1994 3648 3539 283 9.9k
Erich M. Sturgis 4744 2422 3111 3887 302 10.7k
Anthony J. Cmelak 5814 2686 3734 3309 144 9.1k
Primož Strojan 3005 1796 3016 2444 242 7.6k
Sandra Nuyts 2684 1740 1646 1177 213 6.5k

All Works

Loading papers...

Rankless by CCL
2026